Vanguard Group’s Jin Medical International ZJYL Stock Holding History

Vanguard Group’s Portfolio ZJYL Stock Details ZJYL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-72,424	Closed	-$1.13M	–	4307
2024 Q4	$1.13M	Hold	72,424	–	–	﹤0.01%	3726
2024 Q3	$3.9M	Buy	72,424 +35,408	+96%	+$2.13M	﹤0.01%	3364
2024 Q2	$1.92M	Buy	37,016 +35,460	+2,279%	+$2.24M	﹤0.01%	3564
2024 Q1	$119K	Buy	+1,556	New	+$228K	﹤0.01%	4226

Other funds holding ZJYL

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Vanguard Group's ZJYL Position: Q1 2025 in Review

Vanguard Group sold out of Jin Medical International (ZJYL) in Q1 2025, closing a stake of 72,424 shares — an estimated $1.13M sold.

Vanguard Group first reported a position in ZJYL in Q1 2024 and held it in 4 quarters. The position peaked at $3.9M in Q3 2024. 17 funds tracked by Wall St. Rank hold ZJYL as of Q1 2025.

Vanguard Group reported no remaining Jin Medical International position as of Q1 2025 after selling out during the quarter.
Vanguard Group sold 72,424 Jin Medical International shares in Q1 2025, an estimated $1.13M.
Vanguard Group first reported a position in Jin Medical International in Q1 2024 and held it in 4 quarters.
Vanguard Group's Jin Medical International position peaked at $3.9M in Q3 2024.
17 funds tracked by Wall St. Rank held Jin Medical International as of Q1 2025.

Based on Vanguard Group's 13F filing for Q1 2025, filed 9 May 2025.